[go: up one dir, main page]

AR048073A2 - 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene - Google Patents

40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene

Info

Publication number
AR048073A2
AR048073A2 ARP050100744A ARP050100744A AR048073A2 AR 048073 A2 AR048073 A2 AR 048073A2 AR P050100744 A ARP050100744 A AR P050100744A AR P050100744 A ARP050100744 A AR P050100744A AR 048073 A2 AR048073 A2 AR 048073A2
Authority
AR
Argentina
Prior art keywords
rapamycin
pharmaceutical composition
hidroxi
etil
production
Prior art date
Application number
ARP050100744A
Other languages
English (en)
Original Assignee
Novarits Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048073(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novarits Ag filed Critical Novarits Ag
Publication of AR048073A2 publication Critical patent/AR048073A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente se refiere a 40-O-(2-hidroxi-etil)-rapamicina en forma cristalina no solvatada, proceso para producirla en forma sustancialmente pura, que comprende cristalizar 40-O-(2-hidroxi-etil)-rapamicina a partir de un medio de contiene el cristal y recuperar los cristales así obtenidos, y composicion farmacéutica que la comprende.
ARP050100744A 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene AR048073A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
AR048073A2 true AR048073A2 (es) 2006-03-29

Family

ID=26314797

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Country Status (38)

Country Link
US (5) US6605613B2 (es)
EP (4) EP1743657A3 (es)
JP (3) JP3805625B2 (es)
KR (2) KR20060096477A (es)
CN (2) CN1261163C (es)
AR (3) AR026102A1 (es)
AT (1) ATE365051T1 (es)
AU (1) AU759219B2 (es)
BE (1) BE1012869A3 (es)
BR (1) BR9915986A (es)
CA (3) CA2732620C (es)
CO (1) CO4980847A1 (es)
CY (1) CY1106870T1 (es)
CZ (2) CZ303006B6 (es)
DE (1) DE69936352T3 (es)
DK (1) DK1137439T4 (es)
ES (1) ES2288033T5 (es)
FR (1) FR2786771B1 (es)
GB (2) GB9826882D0 (es)
HK (1) HK1038889B (es)
HU (2) HU228939B1 (es)
ID (1) ID29250A (es)
IL (1) IL143092A0 (es)
IT (1) IT1319701B1 (es)
MY (2) MY120594A (es)
NO (2) NO332698B1 (es)
NZ (2) NZ511936A (es)
PE (1) PE20001333A1 (es)
PL (2) PL208854B1 (es)
PT (1) PT1137439E (es)
RU (1) RU2243769C2 (es)
SG (1) SG151072A1 (es)
SI (1) SI1137439T2 (es)
SK (2) SK287325B6 (es)
TR (2) TR200201428T2 (es)
TW (2) TWI248938B (es)
WO (1) WO2000033878A2 (es)
ZA (1) ZA200104360B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
CA2475383C (en) 2002-02-13 2009-12-22 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
TWI307277B (en) * 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
DE04758730T1 (de) * 2003-03-31 2005-06-23 Biogal Gyogyszergyar Rt. Kristallisierung und Reinigung von Makroliden
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005010015A1 (en) 2003-07-24 2005-02-03 Teva Gyogyszergyar Reszvenytarsasag Method of purifying macrolides
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CA2548596A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd. Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2006039237A1 (en) * 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
KR20070104931A (ko) 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
WO2007075621A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
KR20140093764A (ko) * 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
CA2797501A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
EP2601201B1 (en) * 2010-08-04 2014-09-24 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
EP2717884A1 (en) 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (es) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
US10383860B2 (en) 2015-07-28 2019-08-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
EP3342410A4 (en) * 2015-08-28 2019-04-24 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION WITH RAPAMYCIN OR DERIVATIVES THEREOF
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
CN119431400A (zh) * 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DK0593227T3 (da) 1992-10-13 2006-05-01 Wyeth Corp Carbamater af rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
ES2182112T3 (es) * 1996-07-30 2003-03-01 Novartis Ag Composiciones farmaceuticas para el tratamiento del rechazo de transplantes y de estados autoinmunes o inflamatorios, que comprenden ciclosporina a y 40-o-(2-hidroxietil)-rapamicina.
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
AU6041498A (en) 1997-02-04 1998-08-25 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
PE20001333A1 (es) 2000-12-12
GB9826882D0 (en) 1999-01-27
MY120594A (en) 2005-11-30
BE1012869A3 (fr) 2001-04-03
HUP0104489A3 (en) 2004-05-28
US20050107418A1 (en) 2005-05-19
DK1137439T4 (da) 2012-03-19
CA2351580C (en) 2012-03-20
CZ20012001A3 (cs) 2001-09-12
IT1319701B1 (it) 2003-10-27
CN1876657A (zh) 2006-12-13
CZ302210B6 (cs) 2010-12-22
EP1743657A2 (en) 2007-01-17
NZ511936A (en) 2003-10-31
DE69936352T2 (de) 2008-02-14
AU1657300A (en) 2000-06-26
SI1137439T2 (sl) 2012-05-31
ES2288033T3 (es) 2007-12-16
BR9915986A (pt) 2001-09-04
CZ303006B6 (cs) 2012-02-22
JP3805625B2 (ja) 2006-08-02
US6852729B2 (en) 2005-02-08
ZA200104360B (en) 2002-01-16
EP2269651A3 (en) 2011-03-09
US6605613B2 (en) 2003-08-12
ATE365051T1 (de) 2007-07-15
SK287325B6 (sk) 2010-07-07
CN1876657B (zh) 2013-01-09
PL348333A1 (en) 2002-05-20
KR100695834B1 (ko) 2007-03-19
PT1137439E (pt) 2007-09-25
CA2651609A1 (en) 2000-06-15
WO2000033878A2 (en) 2000-06-15
EP2269651A2 (en) 2011-01-05
TWI270550B (en) 2007-01-11
RU2243769C2 (ru) 2005-01-10
CA2351580A1 (en) 2000-06-15
EP1743657A3 (en) 2007-03-28
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
CO4980847A1 (es) 2000-11-27
TR200101416T2 (tr) 2002-01-21
EP2279751A2 (en) 2011-02-02
ITMI992520A1 (it) 2001-06-02
US20030191148A1 (en) 2003-10-09
US7297703B2 (en) 2007-11-20
NO20012424L (no) 2001-05-16
US20020032213A1 (en) 2002-03-14
SI1137439T1 (sl) 2008-06-30
US20080161334A1 (en) 2008-07-03
HU230174B1 (hu) 2015-09-28
JP2005200429A (ja) 2005-07-28
SK286688B6 (sk) 2009-03-05
IL143092A0 (en) 2002-04-21
EP2279751A3 (en) 2011-02-16
FR2786771B1 (fr) 2002-12-27
EP1137439A2 (en) 2001-10-04
AU759219B2 (en) 2003-04-10
HU228939B1 (en) 2013-07-29
ITMI992520A0 (it) 1999-12-02
GB9904934D0 (en) 1999-04-28
JP2006111637A (ja) 2006-04-27
JP5165199B2 (ja) 2013-03-21
US7741338B2 (en) 2010-06-22
DE69936352D1 (de) 2007-08-02
NO20121113L (no) 2001-05-16
HK1038889B (en) 2008-01-25
TR200201428T2 (tr) 2002-12-23
PL208854B1 (pl) 2011-06-30
CA2732620A1 (en) 2000-06-15
EP1137439B1 (en) 2007-06-20
NZ527781A (en) 2004-11-26
WO2000033878A3 (en) 2000-11-02
KR20060096477A (ko) 2006-09-11
US20090270441A1 (en) 2009-10-29
CA2732620C (en) 2013-08-06
EP1137439B2 (en) 2011-11-23
PL196627B1 (pl) 2008-01-31
HUP0104489A2 (hu) 2002-03-28
MY127579A (en) 2006-12-29
NO334612B1 (no) 2014-04-22
KR20010101128A (ko) 2001-11-14
JP5043308B2 (ja) 2012-10-10
DE69936352T3 (de) 2012-05-03
TWI248938B (en) 2006-02-11
AR054444A2 (es) 2007-06-27
SK7662001A3 (en) 2001-12-03
NO332698B1 (no) 2012-12-10
US7572804B2 (en) 2009-08-11
JP2002531527A (ja) 2002-09-24
CN1261163C (zh) 2006-06-28
NO20012424D0 (no) 2001-05-16
TW200540179A (en) 2005-12-16
AR026102A1 (es) 2003-01-29
CN1374872A (zh) 2002-10-16
SG151072A1 (en) 2009-06-29
ES2288033T5 (es) 2012-04-10
FR2786771A1 (fr) 2000-06-09
HK1038889A1 (en) 2002-04-04
ID29250A (id) 2001-08-16

Similar Documents

Publication Publication Date Title
AR048073A2 (es) 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene
DE602004019881D1 (de) Kristallformen der zoledronsäure und deren natrioumsalze, amorphes natriumzoledronat und verfahren zu deren herstellung
ATE422386T1 (de) Verfahren zur herstellung von zeolith-folie deca- dodecasil 3r, zeolith-folie deca-dodecasil 3r und verbund-zeolith-folie deca-dodecasil 3r sowie herstellungsverfahren dafür
MY142926A (en) Method of the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
CY1112347T1 (el) Διεργασια για την κρυσταλλωση της (r)- ή της (s)-λανσοπραζολης
TW200726794A (en) Method for producing cellulose ester film, polarizing plate and liquid crystal display
BRPI0517093B8 (pt) processo para a produção de 8-(3-amino-piperidin-1-il)-xantinas quirais
AR038902A1 (es) Proceso para mejorar la pureza y el rendimiento de la sucralosa
HUP9903454A2 (hu) Cefditoren-pivoxil kristályos formája, és eljárás annak előállítására
NO20062457L (no) Separasjonsprosess
HN2001000110A (es) 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis
ES2128584T3 (es) Procedimiento de desdoblamiento de dos enantiomeros opticos mediante cristalizacion preferencial.
TW200700482A (en) Cellulose ester film, manufacturing method thereof, optical film, polarizing plate and liquid crystal display
MX173709B (es) Un metodo para desarrollar cristales de enzimas
ECSP034927A (es) Método de síntesis técnica para la producción de tropenol
EP1623982A4 (en) METHOD FOR PRODUCING DOCETAXEL TRIHYDRATE
ATE515496T1 (de) Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure
DE60027877D1 (de) Verfahren zur schnellen herstellung von crystallen mit wünschenswerter morphologie
HUP9701747A2 (hu) Eljárás zeolitok előállítására alkáli-alumínium-hidroszilikát-tartalmú nyersanyagokból
ATE480530T1 (de) Herstellungsverfahren für optisch aktive verbindungen
FI20001655A0 (fi) Kiteytysmenetelmä
ATE357426T1 (de) Säulenförmige kristalle von 6-hydroxy-2-naphthyl säure und ein verfahren zu ihrer herstellung
ATE466010T1 (de) Verfahren zur herstellung von candesartan
DE602005013007D1 (de) Verfahren zur herstellung von lactonen
DE60222945D1 (de) Verfahren zur herstellung von cefpodoxim-proxetil

Legal Events

Date Code Title Description
FG Grant, registration